Related Experiment Video

Updated: Apr 1, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β

Marta F Bustamante1, Carlos Morcillo-Suárez1, Sunny Malhotra1

  • 1Servei de Neurologia-Neuroimmunologia (M.F.B., S.M., J.R., X.M., M.C.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Institute of Evolutionary Biology (UPF-CSIC) (C.M.-S., X.F., A.N.), PRBB, Barcelona, Spain; National Institute for Bioinformatics (C.M.-S., X.F., A.N.), Universitat Pompeu Fabra, Barcelona, Spain; Servicio de Neurología (L.L., O.F.), Instituto de Neurociencias Clínicas, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain; Department of Neurology (U.K.Z.), University of Rostock, Rostock, Germany; Department of Neurology (J.K.), Multiple Sclerosis Centre Amsterdam, Vrije University Medical Centre, Amsterdam, the Netherlands; Pole des neurosciences et INSERM U1043 (D.B.), Université de Toulouse III, Hopital Purpan, Toulouse, France; Neuroinmunología (J.A.G.-M., A.J.S.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Servicio de Neurología (E.U., R.A.-L.), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; Department of Neurology and Immunology (L.M.V., J.C.A.-C.), Hospital Ramón y Cajal, IRYCIS, Madrid, Spain; Department of Neurology (J.L.-S.), John Hunter Hospital, Newcastle, Australia; Hunter Medical Research Institute (J.L.-S.), University Newcastle, Australia; University Newcastle (J.L.-S.), Callaghan Campus, Australia; Neurogenomiks Group (K.V.), Universidad del País Vasco (UPV/EHU), Leioa, Spain; IKERBASQUE (K.V.), Basque Foundation for Science, Bilbao, Spain; Achucarro Basque Center for Neuroscience (K.V.), Zamudio, Spain; Servicio de Neurología (A.R.-A.), Hospital de Basurto, Bilbao, Spain; Clinic of Neurology (J.S.D.), Clinical Centre of Serbia (CCS), Faculty of Medicine, University of Belgrade, Serbia; Laboratory of Genetics of Neurological Complex Disorders and Department of Neuro-rehabilitation (F.M.B

Neurology(R) Neuroimmunology & Neuroinflammation
|October 8, 2015
PubMed
Abstract

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.7K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
84
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
147
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
117
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98